Yih-Kai Chan

Yih-Kai Chan

Auto-generated profile, based on publicly available information

Yih-Kai Chan

Australian Catholic University

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
BBBernhard Breier
Bernhard Breier
Mark VickersMark Vickers
Mark Vickers
BIB.A Ikenasio
B.A Ikenasio
KCK.Y Chan
K.Y Chan
WWW.P.S Wong
W.P.S Wong

1 February 2015 in The Lancet
Verified
Journal Article
Closed access
SSSimon Stewart
Simon Stewart
JBJocasta Ball
Jocasta Ball
John HorowitzJohn Horowitz
John Horowitz
TMThomas H Marwick
Thomas H Marwick
GMGnanadevan Mahadevan
Gnanadevan Mahadevan
MCMelinda J Carrington
Melinda J Carrington

1 September 2004 in Diabetes
Verified
Journal Article
Open access
PDF file
GCGarth J. S. Cooper
Garth J. S. Cooper
APAnthony R.J. Phillips
Anthony R.J. Phillips
SCSoon Y. Choong
Soon Y. Choong
BLBridget L. Leonard
Bridget L. Leonard
DCDavid J. Crossman
David J. Crossman
JBJohn R. Baker
John R. Baker
Heart disease is the major cause of death in diabetes, a disorder characterized by chronic hyperglycemia and cardiovascular complications. Although altered systemic regulation of transition metals in diabetes has been the subject of previous investigation, it is not known whether changed transition metal metabolism results in heart disease in common forms of diabetes and whether metal chelation can reverse the condition. We found that administration of the Cu-selective transition metal chelator trientine to rats with streptozotocin-induced diabetes caused increased urinary Cu excretion compared with matched controls. A CuII-trientine complex was demonstrated in the urine of treated rats. In diabetic animals with established heart failure, we show here for the first time that 7 weeks of oral trientine therapy significantly alleviated heart failure without lowering blood glucose, substantially improved cardiomyocyte structure, and reversed elevations in left ventricular collagen and β1 integrin. Oral trientine treatment also caused elevated Cu excretion in humans with type 2 diabetes, in whom 6 months of treatment caused elevated left ventricular mass to decline significantly toward normal. These data implicate accumulation of elevated loosely bound Cu in the mechanism of cardiac damage in diabetes and support the use of selective Cu chelation in the treatment of this condition.

1 October 2012 in JACC
Verified
Journal Article
Closed access
SSSimon Stewart
Simon Stewart
MCMelinda J. Carrington
Melinda J. Carrington
TMThomas H. Marwick
Thomas H. Marwick
PDPatricia M. Davidson
Patricia M. Davidson
PMPeter Macdonald
Peter Macdonald
Paul ScuffhamPaul Scuffham
Paul Scuffham

1 April 2008 in Nutrition
Verified
Journal Article
Closed access
SPSally Poppitt
Sally Poppitt
GKGeraldine F. Keogh
Geraldine F. Keogh
FLFiona E. Lithander
Fiona E. Lithander
YWYu Wang
Yu Wang
TMTom B. Mulvey
Tom B. Mulvey
GCGarth J. S. Cooper
Garth J. S. Cooper

1 May 2005 in Diabetes
Verified
Journal Article
Open access
PDF file
GCGarth J. S. Cooper
Garth J. S. Cooper
YCYih-Kai Chan
Yih-Kai Chan
ADAjith M. Dissanayake
Ajith M. Dissanayake
FLFiona E. Leahy
Fiona E. Leahy
GKGeraldine F. Keogh
Geraldine F. Keogh
SPSally D. Poppitt
Sally D. Poppitt
We recently showed that treatment with the CuII-selective chelator, trientine, alleviates heart failure in diabetic rats, improves left ventricular hypertrophy in humans with type 2 diabetes, and increases urinary Cu excretion in both diabetic rats and humans compared with nondiabetic control subjects. In this study, we characterized the homeostasis of Cu and eight other nutritionally essential elements in diabetes under fully residential conditions in male subjects with type 2 diabetes and age-matched control subjects. We then probed elemental balance with oral trientine in a parallel-group, placebo-controlled study in these subjects. Before treatment, there were no detectable between-group differences in the balance of any element, although urinary output of several elements was greater in diabetic subjects. Mean extracellular superoxide dismutase (EC-SOD) activity was elevated in diabetic subjects, and its activity correlated strongly with the interaction between [Cu]serum and HbA1c. Trientine caused the Cu balance to become negative in diabetic subjects through elevated urinary Cu losses and suppressed elevated EC-SOD. Basal urinary Cu predicted urinary Cu losses during treatment, which caused extraction of systemic CuII. We suggest that cardiovascular complications in diabetes might be better controlled by therapeutic strategies that focus on lowering plasma glucose and loosely bound systemic CuII.